USA-based gene therapy and vaccine company Ocugen (Nasdaq: OCGN) has seen its shares bosted by news that the US Food and Drug Administration is to lift a clinical hold on one the firm’s coronavirus vaccine program.
Development work on the company’s whole virus inactivated COVID-19 jab, Covaxin, will now resume.
The jab is currently in Phase II/III testing, following on from approval in India and a handful of countries, including Iran, Mexico, Greece and Nepal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze